Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This is the third in a series of lunchtime seminars organised by the Oxford BRC Statistics Hub. Each seminar is 20 minutes long followed by 10 minutes of Q&A, and will be held via Microsoft Teams. These seminars are open to all in the University of Oxford and Oxford University Hospitals NHS Trust.

 

Trial designs for early phase trials

Alexander Ooms - OCTRU Senior Medical Statistician

Early phase clinical trials are critical for assessing the safety, dosage, and preliminary efficacy of new treatments. This seminar will outline some available designs in Phase I and Phase II settings.

Phase I trials primarily focus on determining safe dosages and identifying side effects using broad categories of ‘rule-based’ or ‘model-based’ dose escalation methods.

Phase II trials typically aim to give an early indication of treatment efficacy and further assess safety via single-arm or randomised controlled trials. Adaptive, occasionally Bayesian, designs are popular in the early phase setting and some examples of adaptive designs will be discussed.

No registration required.

Click here to join the session.